2019
DOI: 10.1016/j.respe.2019.04.028
|View full text |Cite
|
Sign up to set email alerts
|

ALK-2016-CPHG : caractéristiques des patients présentant un CBNPC ALK+/ROS1+ traités par crizotinib en vie réelle indépendamment de la ligne de traitement

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles